Reading Time: 6 minutes It’s that time of year again when we’re counting down to the annual International Symposium on ALS/MND! This year marks the 35th Symposium, the largest scientific
Author: Mandy Spencer
Reading Time: 10 minutes For the purposes of this blog, ALS should be taken to mean ALS/MND. In September 2020 we published a blog article discussing Dr Rick Bedlack’s
Reading Time: 6 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 7 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 5 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 6 minutes Weight loss is a problem for many people living with MND, with approximately 20% of people already having lost 10% of their weight at diagnosis.
Reading Time: 12 minutes Despite decades of research, we still do not fully understand why some people get MND, but studies in cell and animal models of the disease
Reading Time: 7 minutes Shyuan’s talk was titled ‘Investigating the role of hypermetabolism in ALS’ (C06 in the abstract book) and discussed the research being carried out by her team to try and understand the mechanisms driving hypermetabolism in ALS and what hypermetabolism means clinically for people living with the disease. This blog details Shyuan’s work and looks closely at her observations on hypermetabolism in relation to ALS.
Reading Time: 5 minutes What is a clinical endpoint?
A clinical endpoint is used to determine if the drug that is being tested in a clinical trial is beneficial to the people it is intended to treat – those effects that directly measure how a participant in the trial feels, functions or survives.
To determine a clinical endpoint, it is important to understand how a person with a disease feels and functions, and this is well understood in MND. So, a drug that improves any of these could be seen to be beneficial.